Oxford Biomedica plc Stock

Equities

OXB

GB00BDFBVT43

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:22 2024-06-24 EDT 5-day change 1st Jan Change
309.5 GBX -0.80% Intraday chart for Oxford Biomedica plc +0.98% +40.68%

Financials

Sales 2024 * 129M 164M 224M Sales 2025 * 165M 209M 286M Capitalization 326M 413M 564M
Net income 2024 * -36M -45.67M -62.36M Net income 2025 * -12M -15.22M -20.79M EV / Sales 2024 * 2.38 x
Net cash position 2024 * 18.3M 23.21M 31.7M Net cash position 2025 * 14.94M 18.95M 25.87M EV / Sales 2025 * 1.89 x
P/E ratio 2024 *
-8.48 x
P/E ratio 2025 *
-22 x
Employees 703
Yield 2024 *
-
Yield 2025 *
-
Free-Float 76.68%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.80%
1 week+0.98%
Current month-6.50%
1 month-7.47%
3 months+57.27%
6 months+57.11%
Current year+40.68%
More quotes
1 week
306.50
Extreme 306.5
325.00
1 month
300.00
Extreme 300
344.02
Current year
167.00
Extreme 167
357.39
1 year
164.29
Extreme 164.288
460.00
3 years
164.29
Extreme 164.288
1 678.00
5 years
164.29
Extreme 164.288
1 678.00
10 years
131.30
Extreme 131.3
1 678.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 23-03-26
Director of Finance/CFO 52 17-08-28
Chairman 68 20-06-23
Members of the board TitleAgeSince
Director/Board Member 61 23-04-30
Chairman 68 20-06-23
Director/Board Member 66 16-05-31
More insiders
Date Price Change Volume
24-06-24 309.5 -0.80% 71,462
24-06-21 312 -0.95% 95,195
24-06-20 315 +1.12% 86,509
24-06-19 311.5 -2.20% 65,441
24-06-18 318.5 +3.07% 59,310

Delayed Quote London S.E., June 24, 2024 at 11:35 am

More quotes
Oxford Biomedica plc is a United Kingdom-based cell and gene therapy research, development and bio-processing company. The Company is engaged in providing services to third parties, as well as performing internal research and development for its own purposes. It performs a range of analytical assays within its in-house quality check (QC) labs. The Company operates through two segments: Platform and Product. Platform segment is involved in bio-processing and processes development activities undertaken process by third parties, which is the partner programme for LentiVector and AAV CDMOs business. The segment also includes internal technology developments and technical intellectual property within the LentiVector platform. Product segment consists of the clinical and pre-clinical development of in vivo and ex vivo cell and gene therapy products (gene therapeutics), which are owned by the Company.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.095 GBP
Average target price
4.489 GBP
Spread / Average Target
+45.03%
Consensus